Flovent

(Fluticasone Propionate)

ApprovedSmall molecule

Fluticasone propionate is used to reduce inflammation and relieve symptoms of asthma, allergies, and nasal congestion by decreasing swelling in the airways and sinuses.[2] Flovent is currently approved and in use across 24 indications[4].[1]

Flovent is one of 311 small molecule programs targeting Asthma. It is currently in Approved.

Indications

131

Total Trials

Active Trials

310

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

AsthmaCompleted

Rhinitis, AllergicNot yet recruiting

Skin DiseaseUnknown

Nasal CongestionUnknown

Smoking BehaviorActive, not recruiting

Nicotine DependenceActive, not recruiting

VitiligoActive, not recruiting

Rhinitis, Allergic, PerennialApproved

Chronic BronchitisUnknown

Nasal PolyposisUnknown

AsthmaApproved

Completed

Rhinitis, AllergicApproved

Not yet recruiting

Skin DiseasePreclinical

Unknown

Nasal CongestionPreclinical

Unknown

Smoking BehaviorPreclinical

Active, not recruiting

Nicotine DependencePreclinical

Active, not recruiting

VitiligoPreclinical

Active, not recruiting

Rhinitis, Allergic, PerennialApproved

Approved

Chronic BronchitisPreclinical

Unknown

Nasal PolyposisPreclinical

Unknown

Showing 10 of 24 indications

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Approved

38 2

Celexa

AbbVie

Preclinical

1 3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 8

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1 10

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Allergic Rhinitis (AR)

NCT07537439

Post-ApprovalActive, not recruiting

Study completion

NCT07415278

Post-ApprovalActive, not recruiting

Corticosteroids

NCT02476825

N/AActive, not recruiting

Chronic Rhinosinusitis

NCT04171167

ApprovedNot yet recruiting

Rhinitis, Allergic

NCT07817134

Q3 2027

ApprovedNot yet recruiting

Asthma

NCT07664527

Clinical

Trials by Indication[1]

Asthma38 trials

BI 671800 ED in Steroid-naive Asthmatic Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01092143·389 enrolled

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

Terminated·—·N/A·NCT00706446·255 enrolled

Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years

Completed· GSK logo

GSK··NCT03273946·158 enrolled

Show 35 more trials

Personalized Treatment Algorithms for Difficult-to-treat Asthma

Completed·—·Phase 2·NCT04179461·21 enrolled

12-Week Study in Adult Subjects With Asthma

Completed·DDey·Phase 2·NCT01516073·629 enrolled

Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate

Completed· GSK logo

GSK·Phase 2·NCT00400855·49 enrolled

Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma

Completed·UUniversity of Dundee·Phase 4·NCT00995657·21 enrolled

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01396278·9 enrolled

A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00877539·29 enrolled

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Completed· GSK logo

GSK·Phase 3·NCT01159912·350 enrolled

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01397201·30 enrolled

Viapaed Study In Children And Adolescents With Asthma

Completed· GSK logo

GSK·Phase 4·NCT00315744·285 enrolled

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Completed· GSK logo

GSK·Phase 3·NCT00441441·351 enrolled

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Completed· GSK logo

GSK·Phase 4·NCT00118716·248 enrolled

The Effects of Montelukast on Smokers With Asthma

Completed·IInje University·Phase 4·NCT00712335·105 enrolled

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

Completed·MMilton S. Hershey Medical Center·Phase 3·NCT00395304·182 enrolled

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Completed· GSK logo

GSK·Phase 3·NCT02094937·430 enrolled

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Completed· GSK logo

GSK·Phase 2·NCT03207243·165 enrolled

Study Of RV-39 In Patients Who Also Have Asthma

Terminated· GSK logo

GSK·Phase 4·NCT00503009·16 enrolled

Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

Completed·MMilton S. Hershey Medical Center·Phase 3·NCT00318708·92 enrolled

Study of REGN3500 and Dupilumab in Patients With Asthma

Completed· Regeneron logo

Regeneron·Phase 1·NCT03112577·32 enrolled

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01397162·29 enrolled

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

Completed· GSK logo

GSK·Phase 4·NCT00461500·81 enrolled

Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population

Completed· GSK logo

GSK··NCT01328964·9,906 enrolled

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Completed· GSK logo

GSK·Phase 3·NCT02446418·423 enrolled

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

Completed· GSK logo

GSK·Phase 2·NCT00843193·198 enrolled

Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients

Completed· Novartis logo

Novartis·Phase 2·NCT00814216·37 enrolled

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

Completed·RResearch in Real-Life Ltd··NCT01141439·815,377 enrolled

Study Of Asthma In Patients Of African Descent

Completed· GSK logo

GSK·Phase 4·NCT00102765·479 enrolled

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Completed· GSK logo

GSK·Phase 3·NCT01436110·351 enrolled

A 12-Week Study in Adult Subjects With Asthma

Completed·DDey·Phase 2·NCT01516086·498 enrolled

Study of Safety of Foradil in Patients With Persistent Asthma

Terminated· Novartis logo

Novartis·Phase 4·NCT01845025·827 enrolled

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Completed· GSK logo

GSK·Phase 4·NCT02730351·75 enrolled

Individualized Therapy For Asthma in Toddlers

Completed·MMilton S. Hershey Medical Center·Phase 3·NCT01606306·300 enrolled

Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)

Completed·OOrganon and Co·Phase 3·NCT00127166·154 enrolled

Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications

Completed· GSK logo

GSK·Phase 3·NCT00158834·200 enrolled

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Completed· GSK logo

GSK·Phase 4·NCT00353873·506 enrolled

A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma

Not yet recruiting·UUniversity of Wisconsin, Madison·Approved·NCT07664527·20 enrolled

Allergic Rhinitis12 trials

Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis

Completed·EEgalet Ltd·Phase 1·NCT01365650·24 enrolled

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Terminated· Teva logo

Teva·Phase 3·NCT02246920·1,474 enrolled

Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene

Completed·LLibbs Farmacêutica LTDA·Phase 3·NCT04332978·566 enrolled

Show 9 more trials

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

Withdrawn·SSt. Paul's Sinus Centre·Phase 4·NCT04601324

Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber

Completed· GSK logo

GSK·Phase 1·NCT00404586·45 enrolled

Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)

Completed· GSK logo

GSK·Phase 1·NCT00348361·48 enrolled

The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Terminated·UUniversity of Chicago·Phase 4·NCT00119015·102 enrolled

Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

Completed·PPalau Pharma S.L.U.·Phase 2·NCT01260753·24 enrolled

Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis Patients

Completed·—·Phase 4·NCT06858423·360 enrolled

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

Completed·MMeda Pharmaceuticals·Phase 3·NCT01794741·405 enrolled

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Completed· GSK logo

GSK·Phase 4·NCT00296491·725 enrolled

Study Of Patients With Allergic Rhinitis And Asthma

Completed· GSK logo

GSK·Phase 4·NCT00296530·600 enrolled

Seasonal Allergic Rhinitis7 trials

Investigate Two Trial Models; Vienna Challenge Chamber (in and Out of Season) and Park Study (in Season) Using a Drug for Seasonal Allergic Rhinitis

Completed·RResearch Consult GmbH·Phase 2·NCT00400998·41 enrolled

A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)

Completed· GSK logo

GSK·Phase 2·NCT00612820·55 enrolled

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

Completed·AAlcon Research·Phase 4·NCT00691665·130 enrolled

Show 4 more trials

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

Completed· Pfizer logo

Pfizer·Phase 1·NCT01064726·18 enrolled

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Completed·BBausch & Lomb Incorporated·Phase 2·NCT01578278·606 enrolled

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

Completed·OOrganon and Co·Phase 3·NCT03882047·313 enrolled

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

Completed·UUniversity of Chicago·Phase 4·NCT02402465·22 enrolled

Chronic Obstructive Pulmonary Disease6 trials

A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease

Completed·UUniversity of Dundee·Phase 4·NCT00995475·18 enrolled

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT03240575·302 enrolled

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Completed·DDey·Phase 2·NCT00403286·457 enrolled

Show 3 more trials

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00975195·2,488 enrolled

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Completed·DDey·Phase 2·NCT00774761·97 enrolled

Chronic Obstructive Pulmonary Disease Endpoints Study

Completed· GSK logo

GSK·Phase 4·NCT00358358·163 enrolled

Effectiveness5 trials

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00660517·607 enrolled

Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study

Completed·RResearch in Real-Life Ltd··NCT01287351·82,903 enrolled

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00883168·1,791 enrolled

Show 2 more trials

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00651118·832 enrolled

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00740792·776 enrolled

44 more indications

Corticosteroids4 trials

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00656916·1 enrolled

Effect of Intranasal Corticosteroids on Systemic Allergen Specific IgE

Completed·MMedical University of Vienna·N/A·NCT00755066·48 enrolled

The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children

Terminated·—·Phase 1·NCT03040596·2 enrolled

Show 1 more trial

A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers

Active, not recruiting·UUniversity Hospitals, Leicester·Phase 4·NCT02476825·30 enrolled

Salmeterol3 trials

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Completed·KKindeva Drug Delivery·Phase 1·NCT02232087·52 enrolled

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01969721·229 enrolled

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Completed· Teva logo

Teva·Phase 3·NCT02980133·841 enrolled

MPA2 trials

A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

Completed·MMarc Rothenberg·Phase 3·NCT00266578·30 enrolled

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

Completed·DDey·Phase 1·NCT00280358·30 enrolled

Treatment2 trials

COPD on Primary Care Treatment (COOPT)

Completed·RRadboud University Medical Center·Phase 4·NCT00184977·270 enrolled

FLuticasone in cOvid Treatment (FLOT)

Unknown status·UUniversity of Medicine and Pharmacy at Ho Chi Minh City·Phase 2/3·NCT05054322·500 enrolled

Chronic Rhinosinusitis2 trials

Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis

Withdrawn·SStanford University·Phase 2/3·NCT04242368

The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype

Active, not recruiting·TTampere University Hospital·N/A·NCT04171167·88 enrolled

Lip2 trials

A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT01364519·17 enrolled

Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model

Completed·FFraunhofer-Institute of Toxicology and Experimental Medicine·N/A·NCT01400568·12 enrolled

Children2 trials

Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Completed· GSK logo

GSK·Phase 4·NCT00169546·64 enrolled

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Completed· GSK logo

GSK·Phase 2·NCT01573767·463 enrolled

Eosinophilic Esophagitis2 trials

SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

Completed·—·Phase 2/3·NCT02778867·129 enrolled

Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids

Completed·—·Phase 2/3·NCT02610816·67 enrolled

Chronic Asthma1 trial

A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)

Withdrawn·OOrganon and Co·Phase 3·NCT00540839

Contact Dermatitis1 trial

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Recruiting·WWei-Che Ko·Phase 2/3·NCT05535738·45 enrolled

Nasal polyposis1 trial

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Completed·OOptinose US Inc.·Phase 3·NCT01622569·323 enrolled

Cardiovascular Function1 trial

Cardiovascular Function in COPD Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT03055988·76 enrolled

Esophagitis1 trial

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT05444543·23 enrolled

Blepharitis1 trial

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Completed·NNicox Ophthalmics, Inc.·Phase 2·NCT03926026·36 enrolled

Type 1 Diabetes Mellitus1 trial

The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series

Completed·—·Phase 1·NCT03594565·13 enrolled

ESS1 trial

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

Completed· GSK logo

GSK·Phase 4·NCT00848965·59 enrolled

Endothelial Function1 trial

Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment

Completed·UUniversity of Miami·N/A·NCT02141633·31 enrolled

Inflammation1 trial

Study of Biomarkers of Airway Inflammation (0000-128)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00869596·22 enrolled

Vitamin D1 trial

Vitamin D Plus Fluticasone Propionate

Completed·UUniversity of Chicago·Phase 4·NCT01103934·35 enrolled

Allergic Conjunctivitis1 trial

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Completed·AAndover Research Eye Institute·Phase 4·NCT05314621·61 enrolled

Function1 trial

Enhancement of in-Vitro GC Function in Patients With COPD

Completed·IImperial College London·Phase 2·NCT00241631·49 enrolled

Acute Lymphoblastic Leukemia1 trial

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

Completed· Bayer logo

Bayer·Phase 4·NCT03443843·82 enrolled

Ketorolac1 trial

Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects

Completed·EEgalet Ltd·Phase 1·NCT01365611·36 enrolled

Outcome1 trial

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Completed· GSK logo

GSK··NCT01199757·540 enrolled

Nasal Polyps1 trial

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Completed·OOptinose US Inc.·Phase 3·NCT03591068·11 enrolled

Atopic Dermatitis1 trial

A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis

Completed· GSK logo

GSK·Phase 4·NCT01915914·107 enrolled

Sinusitis1 trial

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Completed·OOptinose US Inc.·Phase 3·NCT01623323·705 enrolled

Bronchiolitis Obliterans1 trial

Targeted Therapy of Bronchiolitis Obliterans Syndrome

Completed·SStephanie Lee·Phase 2·NCT01307462·36 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

Completed·AALK-Abelló A/S·Phase 3·NCT00562159·439 enrolled

Pregnancy1 trial

WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes

Completed· GSK logo

GSK··NCT01681979·1 enrolled

Glaucoma1 trial

Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma

Completed·UUniversity Health Network, Toronto·Phase 4·NCT02338362·22 enrolled

Efficacy1 trial

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

Completed·OORA, Inc.·Phase 4·NCT01439815·22 enrolled

Rhinitis1 trial

Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis

Completed·UUniversity of Dundee·Phase 4·NCT00903227·25 enrolled

Patient Preference1 trial

Fluticasone Nasal Spray Patient Preference Study

Completed· GSK logo

GSK·Phase 3·NCT00398476·127 enrolled

T-ALL1 trial

Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?

Completed·HHamilton Health Sciences Corporation·Phase 4·NCT00716963·7 enrolled

Wheezing1 trial

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Terminated·HHelsinki University Central Hospital·Phase 4·NCT03199976·80 enrolled

Pediatrics1 trial

Qvar vs FP in Pediatrics

Completed·RResearch in Real-Life Ltd··NCT01877954·2,654 enrolled

Randomized1 trial

Randomized Trial of Fluticasone in Bronchial Premalignancy

Completed·AAmsterdam UMC, location VUmc·Phase 2·NCT00407264·90 enrolled

Stridor1 trial

Nebulized Corticosteroid for Post Extubation Stridor in Children

Completed·RRamathibodi Hospital·Phase 3·NCT02523820·144 enrolled

Allergy1 trial

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

Completed· GSK logo

GSK·Phase 3·NCT01817790·626 enrolled

Intranasal Administration1 trial

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Completed·OOptinose US Inc.·Phase 3·NCT01624662·323 enrolled

Rhinitis, Allergic1 trial

An Open Label Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis

Not yet recruiting·HHALEON·Approved·NCT07817134·16 enrolled

Allergic Rhinitis (AR)1 trial

Evaluation Of The Adjunctive Effects Of Moxibustion In The Treatment Of Cold-Syndrome Allergic Rhinitis

Active, not recruiting·UUniversity of Medicine and Pharmacy at Ho Chi Minh City·Preclinical·NCT07537439·60 enrolled

Unspecified9 trials

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Completed· GSK logo

GSK·Phase 3·NCT01018186·503 enrolled

Rhinocort Aqua Versus Placebo and Fluticasone Propionate

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00641680·750 enrolled

A Dose-ranging Study of Fluticasone Furoate (FF)

Completed· GSK logo

GSK·Phase 2·NCT01563029·597 enrolled

Show 6 more trials

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Completed·OOptinose US Inc.·Phase 3·NCT01623310·223 enrolled

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Completed·IIntech Biopharm Ltd.·Phase 1·NCT02466503·45 enrolled

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block

Completed·IIntech Biopharm Ltd.·Phase 1·NCT02466347·45 enrolled

INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION

Active, not recruiting·PPamukkale University·Phase 4·NCT07415278·61 enrolled

Azelastine Fluticasone Combination vs. Fluticasone

Withdrawn·UUniversity of Dundee·Phase 4·NCT00845598

Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate

Withdrawn·UUniversity Hospital, Ghent·N/A·NCT02883439

Regulatory

FDA Approval Timeline[5]

Dec 14, 1990

CUTIVATE

NDA NDA019957

Dec 18, 1990

CUTIVATE

NDA NDA019958

Oct 19, 1994

FLONASE

NDA NDA020121

Mar 27, 1996

FLOVENT

NDA NDA020548

Nov 7, 1997

FLOVENT

NDA NDA020549

Sep 29, 2000

FLOVENT DISKUS 100

NDA NDA020833

May 14, 2004

FLOVENT HFA

NDA NDA021433

Mar 31, 2005

CUTIVATE

NDA NDA021152

Jul 23, 2014

FLONASE ALLERGY RELIEF

NDA NDA205434

Aug 2, 2016

FLONASE SENSIMIST ALLERGY RELIEF

NDA NDA022051

Sep 18, 2017

XHANCE

NDA NDA209022

May 17, 2018

ARNUITY ELLIPTA

NDA NDA205625

Apr 8, 2022

ARMONAIR DIGIHALER

NDA NDA208798

Sources

References

[1]
ClinicalTrials.gov — 131 trial records for Fluticasone Propionate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Flovent drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Fluticasone Propionate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Fluticasone Propionate. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA208798). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Paratek Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PParatek Pharmaceuticals Inc

Flovent

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Asthma38 trials

Allergic Rhinitis12 trials

Seasonal Allergic Rhinitis7 trials

Chronic Obstructive Pulmonary Disease6 trials

Effectiveness5 trials

Corticosteroids4 trials

Salmeterol3 trials

MPA2 trials

Treatment2 trials

Chronic Rhinosinusitis2 trials

Lip2 trials

Children2 trials

Eosinophilic Esophagitis2 trials

Chronic Asthma1 trial

Contact Dermatitis1 trial

Nasal polyposis1 trial

Cardiovascular Function1 trial

Esophagitis1 trial

Blepharitis1 trial

Type 1 Diabetes Mellitus1 trial

ESS1 trial

Endothelial Function1 trial

Inflammation1 trial

Vitamin D1 trial

Allergic Conjunctivitis1 trial

Function1 trial

Acute Lymphoblastic Leukemia1 trial

Ketorolac1 trial

Outcome1 trial

Nasal Polyps1 trial

Atopic Dermatitis1 trial

Sinusitis1 trial

Bronchiolitis Obliterans1 trial

Efficacy and Safety1 trial

Pregnancy1 trial

Glaucoma1 trial

Efficacy1 trial

Rhinitis1 trial

Patient Preference1 trial

T-ALL1 trial

Wheezing1 trial

Pediatrics1 trial

Randomized1 trial

Stridor1 trial

Allergy1 trial

Intranasal Administration1 trial

Rhinitis, Allergic1 trial

Allergic Rhinitis (AR)1 trial

Unspecified9 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News